1. Novo Nordisk remains a sell due to increased competition and regulatory risks despite its leadership in the diabetes and weight-loss markets. 2. Hims & Hers anticipates selling a generic version of NVO's liraglutide, threatening sales as soon as next year. 3. Intense competition from Viking Therapeutics and Amgen may result in a new best-in-class GLP-1 drug, further threatening Novo's market position.